Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ImmunityBio

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2014-01-01

Employees: 628

Market Cap: $2.9B

Website: http://www.immunitybio.com

Introduction: ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Clinical Trials

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Phase 1

Withdrawn

Conditions: Melanoma

Interventions: Biological: Avelumab
Biological: Bevacizumab
Drug: Capecitabine
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: 5-fluorouracil
Drug: Leucovorin
Drug: nab-paclitaxel
Biological: Nivolumab
Drug: omega-3-acid ethyl esters
Radiation: Stereotactic Body Radiation Therapy
Biological: ALT-803
Biological: ETBX-011
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-6207
Biological: GI-6301
Biological: haNK

First Posted Date: 2017-05-25

Last Posted Date: 2025-02-21

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03167177

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Phase 1

Withdrawn

Conditions: Merkel Cell Carcinoma

Interventions: Biological: Avelumab
Biological: Bevacizumab
Drug: Capecitabine
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: 5-fluorouracil
Drug: Leucovorin
Drug: nab-Paclitaxel
Drug: omega-3-acid ethyl esters
Radiation: Stereotactic Body Radiation Therapy
Biological: ALT-803
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-6301
Biological: haNK

First Posted Date: 2017-05-25

Last Posted Date: 2025-02-21

Lead Sponsor: ImmunityBio, Inc.

Registration Number: NCT03167164

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Cyclophosphamide
Drug: Oxaliplatin
Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: nab-paclitaxel
Biological: bevacizumab
Biological: avelumab
Biological: ALT-803
Biological: aNK for Infusion
Biological: ETBX-011
Biological: GI-4000

First Posted Date: 2017-05-02

Last Posted Date: 2024-06-11

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 3

Registration Number: NCT03136406

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Biological: haNK™ for Infusion

First Posted Date: 2017-01-20

Last Posted Date: 2024-11-20

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 6

Registration Number: NCT03027128

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Phase 2

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: N-803 and BCG
Drug: N-803

First Posted Date: 2017-01-18

Last Posted Date: 2025-05-15

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 190

Registration Number: NCT03022825

Locations: 🇺🇸
Integrated Medical Professionals, New York, New York, United States
🇺🇸
Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸
Arkansas Urology, Little Rock, Arkansas, United States

and more 24 locations

QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

Phase 2

Terminated

Conditions: Stage IIIB Merkel Cell Carcinoma
Stage IV Merkel Cell Carcinoma

Interventions: Biological: aNK (NK-92)
Biological: aNK (NK-92) + N-803

First Posted Date: 2015-06-09

Last Posted Date: 2024-05-02

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 7

Registration Number: NCT02465957

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
UPMC Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors

Phase 1

Completed

Conditions: Metastatic Solid Tumors

Interventions: Drug: aldoxorubicin
Drug: gemcitabine

First Posted Date: 2014-09-10

Last Posted Date: 2022-02-10

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 30

Registration Number: NCT02235688

Locations: 🇺🇸
Virginia G. Piper Cancer Center, Scottsdale, Arizona, United States
🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Interventions: Drug: 170 mg/m2 aldoxorubicin
Drug: 250 mg/m2 aldoxorubicin

First Posted Date: 2014-09-10

Last Posted Date: 2024-05-29

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 70

Registration Number: NCT02235701

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Phase 2

Completed

Conditions: Metastatic Small Cell Lung Cancer

Interventions: Drug: Aldoxorubicin
Drug: Topotecan

First Posted Date: 2014-07-25

Last Posted Date: 2024-06-25

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 135

Registration Number: NCT02200757

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
City of Hope Medical Group, Pasadena, California, United States
🇺🇸
Cancer Specialists of North Florida-Fleming Island, Fleming Island, Florida, United States

and more 26 locations

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Phase 1

Recruiting

Conditions: Non-muscle Invasive Bladder Cancer

Interventions: Biological: BCG( 50mg/Instillation)
Biological: BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). )

First Posted Date: 2014-05-15

Last Posted Date: 2024-08-09

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 596

Registration Number: NCT02138734

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Alaska Clinical Research Center, Anchorage, Alaska, United States
🇺🇸
Arkansas Urology, Little Rock, Arkansas, United States

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy